Brief: Novocure’S Optune Lua® Receives CE Mark Approval
22/04/2025 12:42
April 22 (Reuters) - Novocure Ltd NVCR.O: NOVOCURE’S OPTUNE LUA® RECEIVES CE MARK APPROVAL FOR THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER Source text: ID:nBw3Ff1Wwa Further company coverage: NVCR.O
Recent news on NovoCure
See all newsOncology firm Novocure says cyberattack exposed US patient records
Novocure Ltd reports results for the quarter ended June 30 - Earnings Summary
Novocure Q2 revenue beats, lifts 2026 outlook
Brief: Novocure Q2 Revenue USD 183.584 Million Vs. IBES Estimate USD 172.4 Million
U.S. STOCKS ON THE MOVE-Kardigan, Energy companies, Take-Two, Accenture